Top

Published in:

Open Access 01-12-2015 | Research article

Mena^calc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Authors: Catherine L. Forse, Seema Agarwal, Dushanthi Pinnaduwage, Frank Gertler, John S. Condeelis, Juan Lin, Xiaonan Xue, Kimberly Johung, Anna Marie Mulligan, Thomas E. Rohan, Shelley B. Bull, Irene L. Andrulis

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Mena^calc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Mena^calc and risk of death from breast cancer. Our goal was to determine if Mena^calc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer.

Methods

Analysis of the association of Mena^calc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Mena^calc with risk of death after adjustment for HER2 status and clinicopathological tumor features.

Results

High Mena^calc was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Mena^calc cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Mena^calc in the HER2, basal and luminal molecular subtypes.

Conclusions

Mena^calc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.

Available only for authorised users

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50. doi:10.1200/JCO.2013.53.1608.CrossRefPubMedPubMedCentral

Fehrenbacher L, Capra AM, Quesenberry Jr CP, Fulton R, Shiraz P, Habel LA. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32(20):2151–8. doi:10.1200/JCO.2013.52.0858.CrossRefPubMed

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700–6. doi:10.1200/JCO.2009.23.2025.CrossRefPubMedPubMedCentral

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74. doi:10.1073/pnas.191367098.CrossRefPubMedPubMedCentral

Veer LJ V 't, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6. doi:10.1038/415530a.CrossRef

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5), e1000279. doi:10.1371/journal.pmed.1000279.CrossRefPubMedPubMedCentral

Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell. 1996;87(2):227–39.CrossRefPubMed

Barzik M, Kotova TI, Higgs HN, Hazelwood L, Hanein D, Gertler FB, et al. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem. 2005;280(31):28653–62. doi:10.1074/jbc.M503957200.CrossRefPubMedPubMedCentral

Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 2004;109(6):909–18. doi:10.1002/ijc.20094.CrossRefPubMed

10.

Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, et al. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res. 2006;12(5):1470–8. doi:10.1158/1078-0432.CCR-05-2027.CrossRefPubMed

11.

Goswami S, Philippar U, Sun D, Patsialou A, Avraham J, Wang W, et al. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis. 2009;26(2):153–9. doi:10.1007/s10585-008-9225-8.CrossRefPubMed

12.

Gertler F, Condeelis J. Metastasis: tumor cells becoming MENAcing. Trends Cell Biol. 2011;21(2):81–90. doi:10.1016/j.tcb.2010.10.001.CrossRefPubMed

13.

Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004;64(23):8585–94. doi:10.1158/0008-5472.CAN-04-1136.CrossRefPubMed

14.

Wang W, Wyckoff JB, Goswami S, Wang Y, Sidani M, Segall JE, et al. Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res. 2007;67(8):3505–11. doi:10.1158/0008-5472.CAN-06-3714.CrossRefPubMed

15.

Patsialou A, Wang Y, Lin J, Whitney K, Goswami S, Kenny PA, et al. Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res. 2012;14(5):R139. doi:10.1186/bcr3344.CrossRefPubMedPubMedCentral

16.

Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, et al. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital. 2013;2(2), e25294. doi:10.4161/intv.25294.CrossRefPubMedPubMedCentral

17.

Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, et al. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell. 2008;15(6):813–28. doi:10.1016/j.devcel.2008.09.003.CrossRefPubMedPubMedCentral

18.

Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, et al. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci. 2011;124(Pt 13):2120–31. doi:10.1242/jcs.086231.CrossRefPubMedPubMedCentral

19.

Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, et al. Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin Exp Metastasis. 2011;28(6):515–27. doi:10.1007/s10585-011-9388-6.CrossRefPubMedPubMedCentral

20.

Roussos ET, Wang Y, Wyckoff JB, Sellers RS, Wang W, Li J, et al. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Breast Cancer Res. 2010;12(6):R101. doi:10.1186/bcr2784.CrossRefPubMedPubMedCentral

21.

Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–56. doi:10.1158/0008-5472.CAN-06-1823.CrossRefPubMed

22.

Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian B-Z et al. Real-time imaging of the tumor microenvironment reveals local, transient vascular permeability and tumor cell intravasation stimulated by macrophage-derived VEGF. Cancer Discovery. 2015; in press.

23.

Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022–9. doi:10.1158/0008-5472.CAN-04-1449.CrossRefPubMed

24.

Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11(8):573–87. doi:10.1038/nrc3078.CrossRefPubMedPubMedCentral

25.

Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Gen. 2011;7(8), e1002218. doi:10.1371/journal.pgen.1002218.CrossRef

26.

Pignatelli J, Goswami S, Jones JG, Rohan TE, Pieri E, Chen X, et al. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration. Sci Signal. 2014;7(353):ra112. doi:10.1126/scisignal.2005329.CrossRefPubMedPubMedCentral

27.

Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res. 2009;15(7):2433–41. doi:10.1158/1078-0432.CCR-08-2179.CrossRefPubMedPubMedCentral

28.

Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst. 2014;106(8). doi:10.1093/jnci/dju136.

29.

Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, et al. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res. 2012;14(5):R124. doi:10.1186/bcr3318.CrossRefPubMedPubMedCentral

30.

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol. 2004;22(1):86–96. doi:10.1200/JCO.2004.09.128.CrossRefPubMed

31.

Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16(4):1340–9.PubMed

32.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–91. doi:10.1038/sj.bjc.6602678.CrossRefPubMedPubMedCentral

33.

Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011;29(22):2978–84. doi:10.1200/JCO.2010.32.9706.CrossRefPubMedPubMedCentral

34.

Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323–7. doi:10.1038/nm791.CrossRefPubMed

35.

Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol. 2009;520:163–75. doi:10.1007/978-1-60327-811-9_12.CrossRefPubMed

36.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012;25(3):398–404. doi:10.1038/modpathol.2011.174.CrossRefPubMed

37.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71. doi:10.1038/modpathol.3800528.CrossRefPubMed

38.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91. doi:10.1200/JCO.2009.24.9284.CrossRefPubMed

39.

Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114–9.CrossRefPubMed

Title: Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer
Authors: Catherine L. Forse
Seema Agarwal
Dushanthi Pinnaduwage
Frank Gertler
John S. Condeelis
Juan Lin
Xiaonan Xue
Kimberly Johung
Anna Marie Mulligan
Thomas E. Rohan
Shelley B. Bull
Irene L. Andrulis
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1468-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience

Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study

Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?

Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer